03.22.13
Oberg Industries, a Freeport, Pa.-based full-service contract manufacturer of precision metal components and assemblies, has named David Bonvenuto the company’s next president. Current president and CEO, Robert Wagner, will work closely with Bonvenuto over the next few months to ensure a seamless transition of leadership. He also will remain tied to the company as its general counsel and member of the board of directors.
“Bob Wagner has brought a compelling vision and strategy to Oberg Industries starting in 2003 along with a significant focus on customers, quality, and process improvement,” said Eric Oberg, company chairman of the board. “As president, he has driven customer growth and profitability. During the last 10 years the company has been reshaped under his leadership to grow in some of the fastest-growing business segments of the manufacturing sectors and to provide superior quality and customer service. We are grateful that Bob will be staying engaged long term with our business as a member of our board of directors and serving as our general counsel.”
Bonvenuto has been with Oberg Industries since 2001. He has held the position as the company’s chief financial officer and most recently served as the executive vice president and general manager of its wholly-owned subsidiary Oberg Medical. During Bonvenuto’s tenure at Oberg he led the acquisitions and integration efforts of both of the company’s offshore manufacturing facilities in Costa Rica and Mexico. The company credits him for helping Oberg Medical earn the distinction last year as one of Pittsburgh’s 100 fastest-growing companies. Prior to his career with Oberg, Bonvenuto held executive management positions with Wabtec Corporation, MotivePower Industries, Inc., and OnlineChoice.com. He started his career with the global accounting and consulting firm KPMG LLP as a member of its manufacturing audit and consulting practice. He is a graduate of West Virginia University in Morgantown, W.V., and currently serves on the board of directors for the Allegheny Valley Hospital in Pittsburgh, Pa., and the American Heart Association’s Beaver/Butler County Regional Board.
“David brings a strong complement of operational, financial, and strategic planning focus to our customer base and employees,” said Wagner. “He has a clear focus on our customers—their needs both today and into tomorrow, and the ability to position our company to best serve those needs. The most recent success of our Oberg Medical subsidiary as well as the prior work he has done with our domestic and international businesses are testimony to David’s ability to lead our entire organization into the future. I look forward to continuing to work with him to grow our enterprise.”
Oberg Medical focuses on the orthopedic, spine, extremity, endoscopic/laparoscopic, and cardiac rhythm management markets.
Mako Surgical Appoints Sales VP
Mako Surgical Corporation, a Fort Lauderdale, Fla.-based medical robotics company, has promoted Christopher R. Marrus to senior vice president of sales. The company makes the Rio robotic arm interactive orthopedic surgical platform and Restoris implants, both of which are indicated for specific types of osteoarthritic disease.
“Chris has made valuable contributions as a sales leader since joining Mako over a year ago,” said Maurice R. Ferré, M.D., president and CEO of Mako. “Chris has significant experience with both capital and procedural sales, which we believe will greatly assist Mako as we continue to sell additional Rio systems while improving utilization across our installation base.”
Marrus has been with Mako since February 2012, most recently as Mako’s senior director of sales, east. Previously he served as Mako’s regional sales manager for Rio sales, east, from February 2012 to January 2013. Marrus has worked in medical device sales for more than 15 years while managing both capital and procedural sales, national accounts and clinical training. From July 2010 to December 2011, he served as the vice president of U.S. sales for Endogastric Solutions Inc., a medical device company that develops surgical devices for reconstructive gastrointestinal procedures via a transoral approach, where he was responsible for domestic sales and clinical training. Transoral surgery relies on robotics to enter the mouth or throat from within the mouth cavity, rather than through an incision on the throat or neck. From 2004 to 2010, Marrus held various positions with Intuitive Surgical Inc., a surgical robotic company, including area vice president, where he managed a large portion of the company’s national sales team and his responsibilities included both capital and procedural sales. He holds a B.A. in history from Louisiana State University, Baton Rouge, and a J.D. from Tulane University in New Orleans, La.
Mako’s fourth quarter operating report released in January stated that 2,904 “Makoplasty” procedures (arthroplasty procedures that use the Rio robotic arm in surgery) were performed, of which 2,756 were performed at domestic sites and 395 were total hip arthroplasty (THA) procedures. The 2,904 Makoplasty procedures performed represent a 20 percent increase over the procedures performed in the third quarter of 2012 and a 29 percent increase over the procedures performed in the fourth quarter of 2011. The 395 THA procedures performed represent a 31 percent increase over the THA procedures performed in the third quarter of 2012. In the fourth quarter, eleven Makoplasty THA applications were sold, eight of which were sold with the Rio systems sales during the quarter and three of which were sold as upgrades to existing customers with knee-only commercial systems.
According to the company, as of the end of last year, 96 Rio systems, or 62 percent of the worldwide commercial installed base, are Makoplasty THA-enabled.
“We continued to make progress in the fourth quarter toward reestablishing our growth trajectory in Rio system placements and putting the building blocks in place to drive Makoplasty procedure volume and utilization,” said Ferré. “While 2012 was a challenging year for Mako, we believe that the changes we initiated in the second half of the year will position Mako well for improved performance in 2013 and ultimately provide for our long term success.”
Founder of Small Bone Innovations Departs as Company’s Chief
The founder of Small Bone Innovations Inc. (SBI), a Morrisville, Pa.-based orthopedic technology company, has left the firm after eight years. Anthony G. Viscogliosi is returning to the merchant banking business but is leaving SBI in the hands of Michael P. Simpson, who was appointed president and CEO in February 2012. Viscogliosi’s last post at the company was executive chairman.
Viscogliosi said he ended his tenure at SBI to take advantage of growing opportunities in the neuro-musculoskeletal orthopedics industry. He will resume full-time activities as a principal of Viscogliosi Brothers LLC (VB), a merchant banking, venture capital and private equity business that focuses in orthopedic technology.
“Today, SBI is the only pure-play small bone and joint (SBJ) arthroplasty and reconstruction company—with critical mass in revenues, products, balance sheet and global distribution,” Viscogliosi said.
“The company is profitable and growing rapidly, having achieved leadership in the $3 billion SBJ space—the fastest growing segment of the orthopedic device market. VB identified and redefined SBJ treatment as a growth opportunity nearly a decade ago. Having actualized that potential it is time to focus on replicating SBI’s success with VB’s other investments in the neuro-musculoskeletal orthopedics industry.”
VB formed SBI in 2005 by rolling up a few small companies with established products to create a more comprehensive arthroplasty and joint-related trauma reconstruction company. The STAR Total Ankle, acquired by VB and cleared by the U.S. Food and Drug Administration in 2009, has helped SBI cement its footprint in the orthopedic technology sector.
Earlier in his career, Viscogliosi was co-founder, chairman and CEO of Spine Solutions Inc. before it was sold in 2003 to the DePuy division of Johnson & Johnson for $350 million. He also was
a co-founder and board member of the company that later became Ascent Healthcare Solutions Inc., which was sold to Stryker Corp. for $525 million in 2009.
Simpson was named president and CEO last year in preparation for Viscogliosi’s departure. During his career as a division president at Orthofix Holdings Inc., an orthopedic devices company with $575 million in reported revenues in 2011, Simpson managed the global development and international distribution of the firm’s product portfolio, including foot and ankle technologies.
“Our job now,” said Simpson, “is to ensure the company [SBI] and its products become synonymous with the gold standards for preserving the small bones and joints.”
Now that Viscogliosi has moved on, Simpson will report to the SBI board of directors. He is also a member of both SBI’s operating and executive committees. As president and CEO, all officers of the company report to him.
“SBI has a record of redefining the small bone and joint sector by introducing arthroplasty and joint-related trauma technologies such as the STAR Total Ankle and the line of RingFIX lower limb products designed to treat patients with diabetic foot complications,” Simpson said at the time of his appointment last year. “This…platform offers an opportunity to leverage my skills and experience to help SBI extend its penetration of the rapidly growing $3.3 billion small bone and joint market.”
Bonvenuto |
Bonvenuto has been with Oberg Industries since 2001. He has held the position as the company’s chief financial officer and most recently served as the executive vice president and general manager of its wholly-owned subsidiary Oberg Medical. During Bonvenuto’s tenure at Oberg he led the acquisitions and integration efforts of both of the company’s offshore manufacturing facilities in Costa Rica and Mexico. The company credits him for helping Oberg Medical earn the distinction last year as one of Pittsburgh’s 100 fastest-growing companies. Prior to his career with Oberg, Bonvenuto held executive management positions with Wabtec Corporation, MotivePower Industries, Inc., and OnlineChoice.com. He started his career with the global accounting and consulting firm KPMG LLP as a member of its manufacturing audit and consulting practice. He is a graduate of West Virginia University in Morgantown, W.V., and currently serves on the board of directors for the Allegheny Valley Hospital in Pittsburgh, Pa., and the American Heart Association’s Beaver/Butler County Regional Board.
“David brings a strong complement of operational, financial, and strategic planning focus to our customer base and employees,” said Wagner. “He has a clear focus on our customers—their needs both today and into tomorrow, and the ability to position our company to best serve those needs. The most recent success of our Oberg Medical subsidiary as well as the prior work he has done with our domestic and international businesses are testimony to David’s ability to lead our entire organization into the future. I look forward to continuing to work with him to grow our enterprise.”
Oberg Medical focuses on the orthopedic, spine, extremity, endoscopic/laparoscopic, and cardiac rhythm management markets.
Mako Surgical Appoints Sales VP
Mako Surgical Corporation, a Fort Lauderdale, Fla.-based medical robotics company, has promoted Christopher R. Marrus to senior vice president of sales. The company makes the Rio robotic arm interactive orthopedic surgical platform and Restoris implants, both of which are indicated for specific types of osteoarthritic disease.
“Chris has made valuable contributions as a sales leader since joining Mako over a year ago,” said Maurice R. Ferré, M.D., president and CEO of Mako. “Chris has significant experience with both capital and procedural sales, which we believe will greatly assist Mako as we continue to sell additional Rio systems while improving utilization across our installation base.”
Marrus has been with Mako since February 2012, most recently as Mako’s senior director of sales, east. Previously he served as Mako’s regional sales manager for Rio sales, east, from February 2012 to January 2013. Marrus has worked in medical device sales for more than 15 years while managing both capital and procedural sales, national accounts and clinical training. From July 2010 to December 2011, he served as the vice president of U.S. sales for Endogastric Solutions Inc., a medical device company that develops surgical devices for reconstructive gastrointestinal procedures via a transoral approach, where he was responsible for domestic sales and clinical training. Transoral surgery relies on robotics to enter the mouth or throat from within the mouth cavity, rather than through an incision on the throat or neck. From 2004 to 2010, Marrus held various positions with Intuitive Surgical Inc., a surgical robotic company, including area vice president, where he managed a large portion of the company’s national sales team and his responsibilities included both capital and procedural sales. He holds a B.A. in history from Louisiana State University, Baton Rouge, and a J.D. from Tulane University in New Orleans, La.
Mako’s fourth quarter operating report released in January stated that 2,904 “Makoplasty” procedures (arthroplasty procedures that use the Rio robotic arm in surgery) were performed, of which 2,756 were performed at domestic sites and 395 were total hip arthroplasty (THA) procedures. The 2,904 Makoplasty procedures performed represent a 20 percent increase over the procedures performed in the third quarter of 2012 and a 29 percent increase over the procedures performed in the fourth quarter of 2011. The 395 THA procedures performed represent a 31 percent increase over the THA procedures performed in the third quarter of 2012. In the fourth quarter, eleven Makoplasty THA applications were sold, eight of which were sold with the Rio systems sales during the quarter and three of which were sold as upgrades to existing customers with knee-only commercial systems.
According to the company, as of the end of last year, 96 Rio systems, or 62 percent of the worldwide commercial installed base, are Makoplasty THA-enabled.
“We continued to make progress in the fourth quarter toward reestablishing our growth trajectory in Rio system placements and putting the building blocks in place to drive Makoplasty procedure volume and utilization,” said Ferré. “While 2012 was a challenging year for Mako, we believe that the changes we initiated in the second half of the year will position Mako well for improved performance in 2013 and ultimately provide for our long term success.”
Founder of Small Bone Innovations Departs as Company’s Chief
The founder of Small Bone Innovations Inc. (SBI), a Morrisville, Pa.-based orthopedic technology company, has left the firm after eight years. Anthony G. Viscogliosi is returning to the merchant banking business but is leaving SBI in the hands of Michael P. Simpson, who was appointed president and CEO in February 2012. Viscogliosi’s last post at the company was executive chairman.
Viscogliosi |
“Today, SBI is the only pure-play small bone and joint (SBJ) arthroplasty and reconstruction company—with critical mass in revenues, products, balance sheet and global distribution,” Viscogliosi said.
VB formed SBI in 2005 by rolling up a few small companies with established products to create a more comprehensive arthroplasty and joint-related trauma reconstruction company. The STAR Total Ankle, acquired by VB and cleared by the U.S. Food and Drug Administration in 2009, has helped SBI cement its footprint in the orthopedic technology sector.
Earlier in his career, Viscogliosi was co-founder, chairman and CEO of Spine Solutions Inc. before it was sold in 2003 to the DePuy division of Johnson & Johnson for $350 million. He also was
a co-founder and board member of the company that later became Ascent Healthcare Solutions Inc., which was sold to Stryker Corp. for $525 million in 2009.
Simpson was named president and CEO last year in preparation for Viscogliosi’s departure. During his career as a division president at Orthofix Holdings Inc., an orthopedic devices company with $575 million in reported revenues in 2011, Simpson managed the global development and international distribution of the firm’s product portfolio, including foot and ankle technologies.
“Our job now,” said Simpson, “is to ensure the company [SBI] and its products become synonymous with the gold standards for preserving the small bones and joints.”
Now that Viscogliosi has moved on, Simpson will report to the SBI board of directors. He is also a member of both SBI’s operating and executive committees. As president and CEO, all officers of the company report to him.
“SBI has a record of redefining the small bone and joint sector by introducing arthroplasty and joint-related trauma technologies such as the STAR Total Ankle and the line of RingFIX lower limb products designed to treat patients with diabetic foot complications,” Simpson said at the time of his appointment last year. “This…platform offers an opportunity to leverage my skills and experience to help SBI extend its penetration of the rapidly growing $3.3 billion small bone and joint market.”